Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy

Q: What is the clinical evidence from this study?

Study design: Review. Population: Metabolic dysfunction-associated steatotic liver disease (MASLD) with cardiovascular and metabolic comorbidities. Intervention: Incretin-based therapies (GLP-1 receptor agonists, GIP/GLP-1 dual and triple agonists) and sodium-glucose cotransporter 2 inhibitors (SGLT2i).

Q: What does this research mean for the field?

Incretin-based therapies and SGLT2 inhibitors can be clinically prioritized in MASLD through FIB-4-based fibrosis triage and phenotyping across obesity/metabolic burden, ASCVD, and heart failure/CKD. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Yi-Ze Qi; Zhi-Yuan Wang; 李向东

doi:10.4330/wjc.127591

November 5, 2026World Journal of CardiologyOpen Access

Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy

View Full Paper

Ask AI

Bookmark

Share

Key result

FIB-4 triage and clinical phenotyping guide incretin-based therapy and SGLT2 inhibitor selection in MASLD.

Why the study?

Metabolic dysfunction-associated steatotic liver disease often coexists with obesity, diabetes, cardiovascular disease, and CKD, yet cardiovascular clinics frequently do not assess liver fibrosis risk, and combination incretin and SGLT2 inhibitor therapy lacks prospective validation.

Key Points

To establish a clinical decision pathway in cardiovascular practice that integrates fibrosis screening and phenotype stratification to guide incretin and SGLT2 inhibitor therapy for metabolic dysfunction-associated steatotic liver disease (MASLD).
Narrative review framing MASLD within the cardio-hepatic axis for cardiovascular clinicians.
Proposed a two-layer strategy utilizing the fibrosis-4 (FIB-4) index for primary risk triage, followed by clinical stratification into obesity/metabolic burden, atherosclerotic cardiovascular disease, and heart failure or chronic kidney disease phenotypes.
Meta-analytic findings show that patients with MASLD face a significantly higher risk of cardiovascular mortality compared to the general population (HR 1.43, 95% CI: 1.27-1.60).
Incretin-based therapies reduce cardiovascular events and improve steatohepatitis histology, whereas sodium-glucose cotransporter 2 inhibitors yield hard endpoint reductions in heart failure and chronic kidney disease.
Evidence supporting combined incretin and SGLT2 inhibitor therapy is limited to observational signals and lacks prospective clinical trial validation.

Structured PICO

P

Population

Adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and coexisting obesity, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease evaluated in a narrative review.

I

Intervention

Phenotype-guided therapy using fibrosis-4 index (FIB-4) triage to prioritize incretin-based therapies (GLP-1 receptor agonists such as semaglutide and liraglutide, GIP/GLP-1 dual receptor agonists such as tirzepatide, and GIP/GLP-1/glucagon triple receptor agonists such as retatrutide) or sodium-glucose cotransporter 2 inhibitors (SGLT2i such as empagliflozin and dapagliflozin), with fibrosis stage as an independent risk modifier.

Limitations

Narrative mini-review rather than a primary prospective clinical trial.
Liver histological efficacy and cardiovascular/renal outcome evidence derive from separate trials with different populations and endpoints.
Combination therapy with incretin-based agents and SGLT2 inhibitors currently relies on observational signals and lacks prospective validation.
The causal chain linking MASLD, epicardial adipose tissue thickening, and HFpEF lacks direct verification from longitudinal cohorts and mediation analyses.
Evidence for dual (tirzepatide) and triple (retatrutide) receptor agonists comes mainly from phase II or early phase III trials.
Combination therapy of incretin-based therapies and SGLT2i has only observational signals and lacks prospective validation.
Evidence for GLP-1RA in MASH histological improvement and cardiovascular event reduction comes from different trials, different populations, and different primary endpoints, and cannot yet be interpreted as a cross-organ hard endpoint benefit confirmed in the same trial.
The complete causal chain of MASLD to epicardial adipose tissue thickening to HFpEF lacks direct verification from longitudinal cohorts and mediation analyses.
Evidence for emerging dual and triple incretin receptor agonists (tirzepatide, retatrutide) mainly comes from phase II or early phase III trials.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This narrative mini-review proposes a clinical decision framework for patients with MASLD using FIB-4 risk triage and phenotype stratification (obesity/metabolic burden, ASCVD, or HF/CKD) to guide the prioritization of incretin-based therapies and SGLT2 inhibitors.

Abstract

Metabolic dysfunction-associated steatotic liver disease often coexists with obesity, diabetes, cardiovascular disease, and chronic kidney disease (CKD).However, cardiovascular clinics often do not assess liver fibrosis risk.Incretin-based therapies can reduce cardiovascular events and improve steatohepatitis histology.Sodium-glucose cotransporter 2 inhibitors have hard endpoint benefits in heart failure (HF) and CKD.Combination therapy has only observational signals and lacks prospective validation.This review proposes a fibrosis-4 index based triage to identify three phenotypes: Obesity/metabolic burden, cardiovascular disease, and HF/CKD.Fibrosis stage is used as an independent modifier.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qi et al. (2026) conducted a review in Metabolic dysfunction-associated steatotic liver disease (MASLD) with cardiovascular and metabolic comorbidities. Incretin-based therapies (GLP-1 receptor agonists, GIP/GLP-1 dual and triple agonists) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) was evaluated. Incretin-based therapies and SGLT2 inhibitors can be prioritized in MASLD using FIB-4 risk triage and clinical phenotyping across obesity, ASCVD, and heart failure/CKD.

synapsesocial.com/papers/6aefbd4950d2071ffda4bbb7 https://doi.org/10.4330/wjc.127591

View Full Paper

Ask AI

Bookmark

Share

Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading